| Title: | Medicis at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference Transcript |
| Price: | $54.00 |
| Publication Date: | Feb 07, 2008 |
| Source: | Thomson StreetEvents |
| Report Type: | Transcript |
| Abstract: | Final Transcript of MRX presentation, 7-Feb-08 8:40am ET |
| Brief Excerpt: | ... - Merrill Lynch - AnalystFor starters, I've been asked to encourage you to fill out those surveys that you may see in front of you. I believe you can leave them in the back. I'm very pleased to kick it off today with Medicis. As you may know, Medicis is a specialty pharma company focused on cosmetic and therapeutic dermatology and aesthetics in general. The Company markets the leading dermal filler, Restylane for cosmetic use, and Solodyn and Ziana for the treatment of acne, among other products. As you probably know at this point, Medicis is seeking approval for Rolaxin which could be the first botulinum toxin approved for cosmetic use in the U.S. since Botox. I'm very pleased this morning to have with us from Medicis, Mark Prygocki, who has served as the Company's Chief Financial Officer since ####. It is with great pleasure I'll turn the podium over to Mark who will spend ## or ## minutes getting you acquainted or re-acquainted with the Medicis story, then we look forward to your... |
| Word Count: | 7279 |
| Length: | 12 Pages |
| Ticker: | MRX |
| Time: | 8:40am ET |
| Related Report(s): | |
| Format: |
Adobe Acrobat
|
| Free Sample: |
Click
Here
to Download
|
Looking For Something Else?